Investors

Board of Directors
Scott Koenig

Dr. Koenig has been President and Chief Executive Officer of MacroGenics since September 2001. He is Chairman of the Board of Directors at Applied Genetic Technologies Corporation (AGTC) and at the Children’s Research Institute (CRI) of Children’s National Medical Center, and serves as a Board member of MacroGenics, the Biotechnology Industry Organization (BIO), Children’s National Medical Center, and is a member of the Cornell University Council. Prior to joining MacroGenics, he served as Senior Vice President of Research at MedImmune, Inc., where he participated in the selection and maturation of the company's product pipeline for 11 years. From 1984 to 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS.

Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston, where he was elected to Alpha Omega Alpha. He completed his residency in Internal Medicine at the Hospital of the University of Pennsylvania and is Board certified in Internal Medicine and Allergy and Immunology.

David R. Guyer M.D.

Dr. Guyer is Co-Founder, Chief Executive Officer, and Chairman of the Board of Ophthotech Corporation. He has significant medical, drug development and commercial experience in ophthalmology. Prior to joining Ophthotech, Dr. Guyer worked as a venture capitalist and Partner at SV Life Sciences Following a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine, Dr. Guyer co-founded and served as CEO and Director at Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings over $400 million, including a $157 million IPO offering. He has served on the board of directors for many public and private companies. Dr. Guyer graduated summa cum laude from Yale College, receiving his Bachelor of Science degree, and earned his medical degree from the Johns Hopkins University School of Medicine. He completed his ophthalmology residency at the Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

Ed Hurwitz

Ed is a director with Alta. In addition to AGTC, he currently serves on the board of directors of Cara Therapeutics, MacroGenics and Sunesis Pharmaceuticals and led Alta’s investments in Avid Radiopharmaceuticals, Calistoga Pharmaceuticals, ChemoCentryx, FoldRx Pharmaceuticals, Taligen Therapeutics, Threshold Pharmaceuticals and Zafgen. Prior to joining Alta, Ed served as Senior Vice President and CFO of Affymetrix from 1997 to 2002. From 1994 to 1997, Ed was a biotechnology research analyst for Robertson Stephens & Company, and from 1992 to 1994, was a biotechnology research analyst for Smith Barney Shearson. From 1990 to 1992, Ed practiced commercial law at Cooley Godward LLP.

Ed earned his Juris Doctor and Master of Business Administration degrees in 1990 from the University of California, Berkeley’s Boalt School of Law and Haas School of Business, respectively. Ed earned a Bachelor of Arts in Molecular Biology from Cornell University in 1985.

Ivana Magovcevic-Liebisch

Dr. Magovcevic-Liebisch joined Teva as senior Vice President, Head of Global Business Development in April 2013. In this capacity, she is responsible for the execution of transactions identified by Teva’s R&D, Global Franchises and US Specialty teams, including the licensing and/or acquisition of commercial products, drug candidates and technologies. Prior to Teva, Dr. Magovcevic-Liebisch joined Dyax Corp. in April 2001, and had served as an executive officer at the Company since 2005. During her tenure, she held several senior positions within the company, most recently as Executive Vice President and Chief Operating Officer. Prior to Dyax, Dr. Magovcevic-Liebisch was Director of Intellectual Property and Patent Counsel for Transkaryotic Therapies, Inc., Cambridge, MA. Dr. Magovcevic-Liebisch received her Juris Doctor in High Technology law from Suffolk University Law School, Boston, MA and her Doctor of Philosophy in genetics from Harvard University, Cambridge, MA.

Anne M. VanLent

Anne M. VanLent is currently the President of AMV Advisors, an advisory firm which she founded in 2008 to provide corporate strategy and financial consulting services to emerging growth life sciences companies. She currently serves as a director of and chair of the audit committee of Ocera Therapeutics, Inc., a director, member of the Audit Committee and member of the Compliance Committee of Novelion Pharmaceuticals, Inc. (previously Aegerion Pharmaceuticals, Inc.),   and as Lead Independent Director and Audit Chair of Aviragen Pharmaceuticals, Inc. (formerly Biota), all NASDAQ listed companies.  From May 2002 through April 2008, Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a NASDAQ company that developed and marketed prescription dermatology products that was acquired by Stiefel Laboratories in August 2008. From July 1997 to October 2001, she was the Executive Vice President – Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm.  From 1985 to 1993, she served as the Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a publicly-traded biopharmaceutical company. She served as a director, chair of the audit committee and member of the compensation committee of Onconova Therapeutics from July 2013 to May 2016, and as director of Integra Life Sciences Holding Corporation (NasdaqGS: IART) from 1997 to May 2013 and chaired its audit committee from 2006 until 2012. She also served as a director and chair of the audit committee of Penwest Pharmaceuticals, a NASDAQ-listed company from 1998 through its sale to Endo Pharmaceuticals, Inc. in the fall of 2010.  Ms. VanLent received a B.A. degree in Physics from Mount Holyoke College.

James Rosen

Jimmy Rosen is a Partner on Intersouth’s life sciences investment team. He began with the firm as an intern in 2005 while pursuing his graduate degrees; joined full-time in 2007, and became a Partner in 2009. Prior to joining Intersouth, he spent 15 years in clinical, research and financial positions in the health care and biotechnology sectors. Jimmy’s research experience includes programs at the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill, the National Cancer Institute, Duke University Medical Center and its Comprehensive Cancer Center. He also managed and monitored clinical trials at a privately held contract research organization, which led to FDA-approved products. Jimmy spent several years as an equity research analyst at Brean Murray & Co., covering biopharmaceuticals, genomics, generics, drug delivery and medical device companies. Prior to his research and Wall Street functions, he spent five years in Emergency Medical Services as a mountain search & rescue and ambulance medic. Jimmy currently serves on numerous boards and advisory committees, including the Public Health Foundation Board and Dean’s Advisory Council for the Gillings School of Global Public Health at the University of North Carolina, the Board of Visitors for North Carolina Central University, the board of Florida BIO, and the Oversight Committee for the Duke-Coulter Translational Partners Program. He is also a frequent lecturer at Duke, UNC and NC State University. Jimmy holds a B.A. from Duke University and an M.B.A. from UNC-Chapel Hill’s Kenan-Flagler School of Business where he was a Carolina Venture Fellow and recipient of the Frank Hawkins Kenan Award for Excellence. He received his M.S.P.H. from the UNC School of Public Health, where his thesis focused on the relationship between technology transfer in biotechnology and venture capital investment. In 2010 Jimmy was awarded the Eisenhower Fellowship for which he designed and executed a program to evaluate the prospects for health care innovation in China and Southeast Asia.

Sue Washer

An experienced entrepreneur with a strong scientific and operational background, Sue brings a decade of experience in pharmaceutical management and research with Abbott Labs and Eli Lilly & Company and more than 16 years of senior management experience with entrepreneurial firms in Florida including three start-ups. At AGTC, Sue has successfully secured investments of more than $91 million from nationally recognized venture capitalists and granting agencies; negotiated and closed on a major collaboration with a top five Biotech company; lead the company to complete critical milestones; and recruited an experienced management team. Her experience as a group leader with Abbott’s Diagnostic Division helped hone her skills in bringing new products and technologies from the lab bench into the market place.

Sue sits on the board of the University of Florida’s Center for Entrepreneurship, BioFlorida, Southeast BIO, Gainesville Area Innovation Network, and the Florida High Tech Corridor Council. She has a degree in biochemistry from Michigan State University and an MBA from the University of Florida where she was one of the first graduates from the Warrington College of Business Entrepreneurship program.

Investors